Bevacizumab and wound-healing complications: A systematic review and meta-analysis of randomized controlled trials

Oncotarget

Volumn 7, Issue 50, 2016, Pages 82473-82481

  Zhang, Hongliang ^a   Huang, Zhenguang ^a   Zou, Xiaoqin ^a   Liu, Taotao ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Bevacizumab; Meta analysis; Systematic review; Wound healing complications

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR;

ARTICLE; BREAST CANCER; COLON CARCINOMA; DRUG EFFICACY; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; GASTRO ESOPHAGEAL ADENOCARCINOMA; HUMAN; INCIDENCE; KIDNEY METASTASIS; META ANALYSIS; METASTATIC COLORECTAL CANCER; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SYSTEMATIC REVIEW; WOUND HEALING IMPAIRMENT; ADJUVANT CHEMOTHERAPY; CHI SQUARE DISTRIBUTION; DRUG EFFECTS; NEOADJUVANT THERAPY; NEOPLASM; ODDS RATIO; RISK FACTOR; WOUND HEALING;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; HUMANS; NEOADJUVANT THERAPY; NEOPLASMS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; WOUND HEALING;

EID: 85004098409     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12666     Document Type: Article

References (31)

1. Sharma K, Marcus JR. Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon. Ann Plast Surg. 2013; 71:434-440.
2. FDA Commissioner Removes Breast Cancer Indication from Avastin Label. http://wwwfdagov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm193900htm. 11/18/2011.
3. Mansour J, Fields B, Macomson S, Rixe O. Significant antitumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme. Target Oncol. 2014; 9:395-398.
4. Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol. 2006; 33:S1-7.
5. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res. 2006; 66:1434-1445.
6. Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, Bagnard D, Roche J. Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherinmediated cell adhesion. Neoplasia. 2005; 7:180-189.
7. Chen Z, Zhong B, Lun X, Lai Y, Bella AE, Yang W, Wu J. Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC: A Meta-Analysis. Medicine. 2015; 94:e975.
8. Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005; 91:173-180.
9. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370:2103-2111.
10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350:2335-2342.
11. Okines AF, Langley RE, Thompson LC, Stenning SP, Stevenson L, Falk S, Seymour M, Coxon F, Middleton GW, Smith D, Evans L, Slater S, Waters J, et al. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann Oncol. 2013; 24:702-709.
12. Guan ZZ, Xu JM, Luo RC, Feng FY, Wang LW, Shen L, Yu SY, Ba Y, Liang J, Wang D, Qin SK, Wang JJ, He J, et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer. 2011; 30:682-689.
13. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, Lopa SH, Petrelli NJ, Goldberg RM, Atkins JN, Seay TE, Fehrenbacher L, O'Reilly S, Chu L, et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009; 27:3385-3390.
14. Blumenschein GR, Jr., Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, Sun YN, Sikorski R, et al. Motesanib NPIISI. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2011; 22:2057-2067.
15. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010; 28:3239-3247.
16. Gerber B, von Minckwitz G, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Solbach C, Jackisch C, Kunz G, et al. Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44). Ann Surg Oncol. 2014; 21:2517-2524.
17. Sharma and Ketan. Bevacizumab and Wound-Healing Complications: A Systematic Review. 2011.
18. Goulart BH, Ramsey SD, Parvathaneni U. Observational study designs for comparative effectiveness research: an alternative approach to close evidence gaps in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2014; 88:106-114.
19. Bothwell LE, Greene JA, Podolsky SH, Jones DS. Assessing the Gold Standard-Lessons from the History of RCTs. N Engl J Med. 2016; 374:2175-2181.
20. Ahmadizar F, Onland-Moret NC, de Boer A, Liu G, Maitland-van der Zee AH. Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PloS One. 2015; 10:e0136324.
21. Lee S, Go J, Rhiu S, Stulting RD, Lee M, Jang S, Lee S, Kim HJ, Chung ES, Kim S, Seo KY. Cosmetic regional conjunctivectomy with postoperative mitomycin C application with or without bevacizumab injection. Am J Ophthalmol. 2013; 156:616-622 e613.
22. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009; 43:490-501.
23. Avastin (bevacizumab) label information. 2015, Genentech, Inc: South San Francisco.
24. Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010; 11:373-382.
25. Ignoffo RJ. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm. 2004; 61:S21-26.
26. Etxano J, Insausti LP, Elizalde A, Lopez Vega JM, Plazaola A, Martinez P. Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy. Acta Radiol (Stockholm, Sweden: 1987). 2015; 56:1300-1307.
27. Formica V, Luccchetti J, Cunningham D, Smyth EC, Ferroni P, Nardecchia A, Tesauro M, Cereda V, Guadagni F, Roselli M. Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. Med Oncol. 2014; 31:166.
28. Petrelli F, Coinu A, Cabiddu M, Borgonovo K, Lonati V, Ghilardi M, Barni S. Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11, 585 patients. Med Oncol. 2015; 32:456.
29. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 (http://handbook. cochrane.org/). 2011.
30. Cui Y, Zong H, Zhang Y. The efficacy and safety of silodosin in treating BPH: a systematic review and metaanalysis. Int Urol Nephrol. 2012; 44:1601-1609.
31. Yang CS, Huang H, Zhang LL, Zhu CR, Guo Q. Aripiprazole for the treatment of tic disorders in children: a systematic review and meta-analysis. BMC Psychiatry. 2015; 15:179.